1. Scrip
  2. >>R&D
  3. >>Clinical Trials

ELEVATE Data Raise PureTech’s IPF Prospects

 
• By Kevin Grogan

The company’s deupirfenidone, a selectively deuterated version of Roche's Esbriet, has bested the original in a Phase IIb trial in idiopathic pulmonary fibrosis patients. Now, PureTech can finalize the Phase III program and decide how to finance it.

Neon Light Sign Lungs Icon
• Source: Shutterstock

PureTech Health’s bid to change the treatment paradigm for idiopathic pulmonary fibrosis (IPF) has been boosted by mid-stage data on its candidate that appears to have overcome the tolerability issues of the standard-of-care drugs for the progressive and fatal lung disease.

The company has presented what it claims are groundbreaking results from ELEVATE IPF, a Phase IIb trial evaluating deupirfenidone (also known as LYT-100), a selectively deuterated form of Roche’s blockbuster IPF drug Esbriet (pirfenidone)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor For IPF

 
• By Dexter Jie Yan

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

More from Business

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.

AbbVie On MFN: ‘We Have To Take It Seriously’

 
• By Jessica Merrill

AbbVie chief commercial officer Jeffrey Stewart called Trump’s drug pricing plan a “disruption” but said ultimately the delta between US and EU drug prices may not be as high as some expect.

Industry Leaders Grapple With Trump’s MFN Pricing Plan

 
• By Jessica Merrill

At the Bank of America health care conference, pharma leaders speculated on what Trump’s executive order on drug pricing could mean for US and European drug prices.